Status:
TERMINATED
Evaluate the Performance of JOURNEY II CR in TKA Populations
Lead Sponsor:
Smith & Nephew, Inc.
Conditions:
Arthroplasty
Replacement
Eligibility:
All Genders
18-80 years
Brief Summary
Background: The JOURNEY II CR Total Knee System consists of femoral component made from oxidized zirconium (OXINIUM) Purpose: Post-market evidence generation for JOURNEY II CR Total Knee System Ob...
Eligibility Criteria
Inclusion
- Subjects with degenerative osteoarthritis.
- Subject is planning to have TKA using JOURNEY II CR.
- Subject is able and willing to provide voluntary consent to study participation.
- Subject is 18-80 years old (inclusive) \* (\* For Japan, the minimum inclusion age is 20 years old.)
Exclusion
- Subjects with rheumatoid arthritis/inflammatory arthritis, posttraumatic arthritis.
- Previous surgeries including HTO, UKA or TKA on the subject knee.
- Subject is pregnant or breast feeding or those at a child-bearing age planning to become pregnant during the follow up.
- Subject does not meet the indication or is contraindicated for JOURNEY II CR's IFU.
Key Trial Info
Start Date :
March 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2024
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04818840
Start Date
March 3 2022
End Date
March 15 2024
Last Update
August 20 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China, 100083
2
Prince of Wales Hospital
Hong Kong, China
3
Aster RV Hospital, Bangalore
Bengaluru, Karnataka, India, 560078
4
Arcus Hospital
Pune, Maharashtra, India, 411040